Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
On Friday, JMP Securities maintained a positive stance on Solid Biosciences (NASDAQ:SLDB), currently trading at $2.59, reiterating a Market Outperform rating and a $15.00 price target. The stock, which has fallen over 70% in the past year, sits near its 52-week low of $2.41. The firm’s analyst highlighted the potential for Solid Biosciences’ gene therapy, SGT-003, following promising clinical data and anticipated regulatory discussions later in the year. According to InvestingPro analysis, the company appears undervalued despite recent challenges.
The recent First-in-Human (FiH) data readout for SGT-003 in February 2025 surpassed expectations, showcasing notable mean microdystrophin expression, high copy numbers, and early signs of muscle integrity improvement. These results have contributed to the firm’s confidence in the therapy’s prospects.
JMP’s analysis included insights from a Key Opinion Leader (KOL) call with Dr. Edward C. Smith, who expressed interest in the early yet remarkable outcomes observed in the INSPIRE DUCHENNE study. Dr. Smith’s perspective, as a clinician and trial investigator, adds credence to the therapy’s initial success.
The biotech company’s therapy is aimed at treating Duchenne Muscular Dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration. The analyst anticipates that forthcoming results involving more than ten patients, along with regulatory updates following discussions with the FDA in the second half of 2025, will further solidify the therapy’s potential and clarify the pathway for accelerated approval.
The focus now turns to the future milestones for Solid Biosciences, as the biopharmaceutical industry and investors await the continuation of SGT-003’s clinical journey and its potential to address the unmet needs in DMD treatment.
In other recent news, Solid Biosciences has been in the spotlight following the release of promising clinical data from its Phase 1/2 INSPIRE DUCHENNE trial for the gene therapy candidate SGT-003. The company reported that the therapy achieved an average microdystrophin expression of 110% among initial participants, which has been well-received due to its potential cardiac benefits and favorable safety profile. Analysts from H.C. Wainwright have responded positively by raising the price target for Solid Biosciences to $20, citing the promising clinical data and increasing the likelihood of the therapy’s market launch. JMP Securities also maintained their Market Outperform rating with a $15 price target, highlighting the therapy’s superior performance compared to competitors and the company’s improved financial position following a recent capital raise.
Additionally, the company plans to engage with the FDA to explore an accelerated approval pathway for SGT-003, which could expedite its availability to patients. Analysts from Truist and Leerink Partners have noted the therapy’s potential to impact the Duchenne muscular dystrophy treatment landscape significantly. Meanwhile, a broader shakeup in the biotech sector has been observed due to the resignation of Dr. Peter Marks from the FDA, which has caused concern about possible changes in regulatory processes. This development has affected several biotech firms, including Solid Biosciences, as the market evaluates the implications of this regulatory change.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.